Benitec Biopharma (BNTC) Set to Release Quarterly Earnings on Monday

Benitec Biopharma (NASDAQ:BNTC) is expected to release its Q4 2026 results before the market opens on Monday, September 28th. Analysts expect Benitec Biopharma to post earnings of ($0.2686) per share for the quarter. Investors can check the company’s upcoming Q4 2026 earning summary page for the latest details on the call scheduled for Monday, September 14, 2026 at 4:00 PM ET.

Benitec Biopharma (NASDAQ:BNTC) last announced its quarterly earnings data on Monday, September 14th. The biotechnology company reported ($0.26) EPS for the quarter, meeting analysts’ consensus estimates of ($0.26). On average, analysts expect Benitec Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Benitec Biopharma Stock Down 0.5%

BNTC opened at $9.59 on Friday. The firm has a market cap of $334.50 million, a PE ratio of -9.79 and a beta of 0.27. The business has a fifty day simple moving average of $12.16 and a 200-day simple moving average of $12.01. Benitec Biopharma has a fifty-two week low of $9.26 and a fifty-two week high of $16.76.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on BNTC. Citigroup reiterated a “market outperform” rating on shares of Benitec Biopharma in a research report on Tuesday, September 15th. Wedbush upped their price objective on shares of Benitec Biopharma from $16.00 to $17.00 and gave the company an “outperform” rating in a research note on Tuesday, September 15th. Royal Bank Of Canada upgraded shares of Benitec Biopharma to an “outperform” rating in a report on Tuesday, September 15th. Guggenheim downgraded shares of Benitec Biopharma from a “buy” rating to a “neutral” rating in a research report on Wednesday, June 10th. Finally, Wall Street Zen cut Benitec Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, September 19th. Seven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $24.00.

Benitec Biopharma Company Profile

Benitec Biopharma Inc (NASDAQ:BNTC) is a clinical-stage biotechnology company developing genetic medicines based on DNA-directed RNA interference (ddRNAi). The company’s technology is designed to enable long-lasting suppression of disease-causing genes by delivering genetic instructions that produce RNA interference molecules within targeted cells.

Benitec’s lead product candidate is BB-301, an investigational gene therapy being developed for oculopharyngeal muscular dystrophy type 1 (OPMD), a rare inherited disorder that can cause progressive weakness of the muscles involved in swallowing and eye movement.